About Us
Company Overview
Vision / Mission / Values
Leadership
Clinical Advisory Board
Partnering
Our Approach
Technologies
Manufacturing
Publications
Pipeline
Pipeline
Autologous CAR-T
Allogeneic CAR-T
Expanded Access
Investors
Announcements
Corporate Governance
Corporate Deck & Presentations
Webcasts
Presentations
Financial Reports
Listing Documents
IR Contact
Newsroom
Careers
Join Us
Contact Us
EN
简
About Us
Company Overview
Vision / Mission / Values
Leadership
Clinical Advisory Board
Partnering
Our Approach
Technologies
Manufacturing
Publications
Pipeline
Pipeline
Autologous CAR-T
Allogeneic CAR-T
Expanded Access
Investors
Announcements
Corporate Governance
Corporate Deck & Presentations
Webcasts
Presentations
Financial Reports
Listing Documents
IR Contact
Newsroom
Careers
Join Us
Contact Us
Claudin18.2 CAR T Cells (CT041) Receives Approval to Initiate A Confirmatory Phase II Clinical Trial for advanced GC/GEJ in China
Home
-
Newsroom
-
Newsroom
Claudin18.2 CAR T Cells (CT041) Receives Approval to Initiate A Confirmatory Phase II Clinical Trial for advanced GC/GEJ in China
Mar 03, 2022
Previous
Next